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ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia characterized by amyloid 
plaques and neurofibrillary tangles in the brain. Novel biomarkers for AD are needed that 
reflect disease progression and could identify subjects at risk of developing AD at an 
asymptomatic stage. The aim of this thesis was to develop methods that can be used to 
quantify endogenous peptides and proteins in cerebrospinal fluid (CSF) to identify potential 
biomarkers for AD. 
A workflow was developed for preparation of peptide extracts from CSF. The endogenous 
peptides from CSF were identified by tandem mass spectrometry, and several novel 
endogenous peptides were found. To quantify the endogenous peptides in CSF, isobaric 
labeling for relative quantification was incorporated into the workflow. A clinical cohort with 
CSF samples from AD patients and controls was then analyzed with the method to identify 
potential biomarkers for AD. Several alterations among the endogenous peptides and proteins 
were found in the AD group. Altered endogenous peptides derived from proteins that affect 
e.g. Aβ aggregation, such as integral membrane protein 2B, and from proteins that have been 
reported as associated with AD, such as neurosecretory protein VGF, metallothionein-3 and 
secretogranin-1. Increased levels of the protein YKL-40 were found in the CSF of AD patients 
as well as alterations in novel potential protein biomarkers.  
Human CSF samples from a γ-secretase inhibitor (GSI) trial were also analyzed with the 
developed workflow to identify potential biomarkers for γ-secretase activity. Endogenous 
peptides from amyloid precursor-like protein 1 (APLP1), apolipoprotein E, proSAAS, 
secretogranin-1 and metallothionein-3 were significantly lowered in subjects who received the 
GSI compared to those who received a placebo. Two peptides from APLP1, which is a known 
γ-secretase substrate, were identified as decreased and could be potential biomarkers for γ-
secretase activity. The other endogenous peptides were derived from proteins that are not 
known γ-secretase substrates but were nevertheless decreased.  
In summary, the developed method could be used to identify novel biomarkers for diseases 
affecting the brain, and for monitoring treatment effects of substances which have their target 
in the brain. Several potential CSF biomarkers were identified for AD and for γ-secretase 
activity. 
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